India, May 27 -- As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights into the rapidly evolving use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as Ozempic in the Australian healthcare system.

Originally developed for type 2 diabetes, GLP-1 RAs have gained significant traction globally for obesity treatment. With 32 per cent of Australians classified as obese in 2022 and the cost of obesity projected to reach $87.7 billion in Australia by 2032, this review for the Medical Journal of Australia highlights the critical need to carefully plan how these medications are used.

Associate Professor Suong Le, a gastroenterologist at Monash University's School o...